[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE20151809A1 - Procesos para la preparacion de un agente inductor de la apoptosis - Google Patents

Procesos para la preparacion de un agente inductor de la apoptosis

Info

Publication number
PE20151809A1
PE20151809A1 PE2015001892A PE2015001892A PE20151809A1 PE 20151809 A1 PE20151809 A1 PE 20151809A1 PE 2015001892 A PE2015001892 A PE 2015001892A PE 2015001892 A PE2015001892 A PE 2015001892A PE 20151809 A1 PE20151809 A1 PE 20151809A1
Authority
PE
Peru
Prior art keywords
preparation
inducing agent
apoptosis inducing
processes
organic solvent
Prior art date
Application number
PE2015001892A
Other languages
English (en)
Inventor
Jufang Barkalow
Jean-Christophe Califano
Vincent S Chan
Alan C Christensen
Timothy A Grieme
Yi-Yin Ku
Mathew M Mulhern
Yu-Ming M Pu
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of PE20151809A1 publication Critical patent/PE20151809A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/455Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation with carboxylic acids or their derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00Compounds having —CHO groups
    • C07C47/38Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings
    • C07C47/457Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings containing halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/30Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se refiere a un proceso para la preparacion de un agente inductor de la apoptosis, y sustancias quimicas intermediarias del mismo. Tambien, novedosas sustancias quimicas intermediarias relacionadas con dicho proceso. Este proceso consiste en la combinacion de un compuesto de formula K con una sal tert-butoxido, un solvente organico aprotico y agua. Finalmente se combina con clorhidrato de 1-etil-3-(3-dimetilaminopropil)carbodiimida, 4-dimetilaminopiridina, un solvente organico y un derivado de nitro-bencenosulfonamida
PE2015001892A 2013-03-13 2014-03-12 Procesos para la preparacion de un agente inductor de la apoptosis PE20151809A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361780621P 2013-03-13 2013-03-13
US201461947850P 2014-03-04 2014-03-04

Publications (1)

Publication Number Publication Date
PE20151809A1 true PE20151809A1 (es) 2015-12-25

Family

ID=50439506

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2015001892A PE20151809A1 (es) 2013-03-13 2014-03-12 Procesos para la preparacion de un agente inductor de la apoptosis
PE2019001821A PE20191685A1 (es) 2013-03-13 2014-03-12 Procesos para la preparacion de un agente inductor de la apoptosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2019001821A PE20191685A1 (es) 2013-03-13 2014-03-12 Procesos para la preparacion de un agente inductor de la apoptosis

Country Status (31)

Country Link
EP (5) EP3293185A1 (es)
JP (2) JP6357220B2 (es)
KR (1) KR102230339B1 (es)
CN (3) CN105164128B (es)
AU (2) AU2014248742B2 (es)
BR (3) BR112015021540B1 (es)
CA (3) CA3183040A1 (es)
CL (1) CL2015002548A1 (es)
CR (1) CR20150495A (es)
CY (1) CY1120576T1 (es)
DK (1) DK2970263T3 (es)
ES (1) ES2683378T3 (es)
HK (1) HK1251231A1 (es)
HR (1) HRP20181273T1 (es)
HU (1) HUE039046T2 (es)
IL (2) IL240779B (es)
LT (1) LT2970263T (es)
MX (2) MX365343B (es)
MY (1) MY192466A (es)
PE (2) PE20151809A1 (es)
PH (2) PH12015501960B1 (es)
PL (1) PL2970263T3 (es)
PT (1) PT2970263T (es)
RS (1) RS57569B1 (es)
RU (1) RU2660424C2 (es)
SG (2) SG10201701680YA (es)
SI (1) SI2970263T1 (es)
TW (2) TWI631121B (es)
UA (1) UA118667C2 (es)
UY (3) UY39847A (es)
WO (1) WO2014165044A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104370905B (zh) * 2014-10-22 2016-06-01 南京友杰医药科技有限公司 Bcl-2抑制剂ABT-199的合成
US11001582B2 (en) 2016-03-10 2021-05-11 Assia Chemical Industries Ltd. Solid state forms of Venetoclax and processes for preparation of Venetoclax
CN107089981A (zh) * 2017-04-24 2017-08-25 杭州科耀医药科技有限公司 一种BCL‑2抑制剂Venetoclax的合成方法
AU2018322059C1 (en) 2017-08-23 2024-09-12 Guangzhou Lupeng Pharmaceutical Company Ltd. BCL-2 inhibitors
CN108037196B (zh) * 2017-11-23 2020-06-23 中山奕安泰医药科技有限公司 一种3-硝基-4-[[(四氢-2h-吡喃-4-基)甲基]氨基]苯磺酰胺的检测方法
WO2019139900A1 (en) 2018-01-10 2019-07-18 Zeno Royalties & Milestones, LLC Benzamide compounds
WO2020003272A1 (en) 2018-06-29 2020-01-02 Fresenius Kabi Oncology Ltd. An improved process for the preparation of venetoclax
CN108997333A (zh) * 2018-07-04 2018-12-14 江苏中邦制药有限公司 一种b细胞淋巴瘤因子-2抑制剂abt-199的制备方法
WO2020023435A1 (en) 2018-07-24 2020-01-30 Albany Molecular Research, Inc. Venetoclax basic salts and processes for the purification of venetoclax
US11903950B2 (en) 2018-08-22 2024-02-20 Newave Pharmaceutical Inc. BCL-2 inhibitors
WO2020049599A1 (en) * 2018-09-07 2020-03-12 Msn Laboratories Private Limited, R&D Center Process for the preparation of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1- yl]methyl}piperazin-1-yl)-n-({3-nitro-4-[(tetrahydro-2h-pyran-4-ylmethyl)amino] phenyl}sulfonyl)-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide)
CN112079795B (zh) * 2020-09-16 2022-12-09 广东莱佛士制药技术有限公司 一种维奈托克中间体及其类似物的合成方法
IT202100025976A1 (it) 2021-10-06 2023-04-06 Univ Degli Studi Di Perugia Combinazione di principi attivi per il trattamento della leucemia acuta mieloide (LAM) con mutazione della nucleofosmina (NPM1)
CN114163369A (zh) * 2021-12-17 2022-03-11 武汉工程大学 一种含硫/氧酯基芳烃化合物的制备方法
CN116496239A (zh) * 2022-12-14 2023-07-28 南京哈柏医药科技有限公司 一种维奈托克关键中间体及原料药的合成方法
EP4421075A1 (en) 2023-02-27 2024-08-28 KRKA, d.d., Novo mesto Process for the preparation of venetoclax and intermediates used therein

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB585940A (en) 1944-09-01 1947-02-28 Kodak Ltd Bicyclic compounds containing the diphenylamine grouping, process of making them and their use in the colouration of textile materials other than cellulose
US3813443A (en) 1970-11-18 1974-05-28 Us Agriculture Boll weevil sex attractant
CZ305827B6 (cs) 1999-02-10 2016-03-30 Astrazeneca Ab Indolové deriváty
KR101278522B1 (ko) 2004-12-02 2013-06-25 다이이찌 산쿄 가부시키가이샤 7원환 화합물 및 그 제조법 및 의약 용도
CN1827582A (zh) * 2006-04-18 2006-09-06 江苏中丹化工集团公司 6-[3-(1-金刚烷基)-4-甲氧基苯基]-2-萘甲酸甲酯的制备方法
MX2009011754A (es) * 2007-04-30 2009-12-01 Abbott Lab Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1.
CN102036969A (zh) 2008-03-20 2011-04-27 雅培制药有限公司 制造作为trpv1拮抗剂的中枢神经系统药剂的方法
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
WO2010083441A2 (en) * 2009-01-19 2010-07-22 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
CN101990094B (zh) 2009-08-05 2012-11-21 炬力集成电路设计有限公司 一种码流分析方法和装置
CN102030651A (zh) * 2009-09-28 2011-04-27 莱阳市盛华科技有限公司 2-氟-4-溴联苯基甲酸乙酯的合成方法
TWI520960B (zh) * 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
DE102010027213A1 (de) * 2010-07-15 2012-01-19 Continental Automotive Gmbh Verfahren und Steuergerät zum Steuern einer Brennkraftmaschine
KR20180059560A (ko) 2010-10-29 2018-06-04 애브비 인코포레이티드 아폽토시스―유도제를 포함하는 고체 분산체
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CA2820618C (en) 2010-11-23 2020-04-21 Steven Elmore Use of sulfonylbenzamide compounds in the treatment of systemic lupus erythematosus, lupus nephritis, or sjogren's syndrome
RU2628560C2 (ru) 2010-11-23 2017-08-18 Эббви Инк. Соли и кристаллические формы индуцирующего апоптоз агента

Also Published As

Publication number Publication date
NZ751139A (en) 2020-10-30
HUE039046T2 (hu) 2018-12-28
JP2018138571A (ja) 2018-09-06
IL240779B (en) 2018-04-30
WO2014165044A1 (en) 2014-10-09
JP6357220B2 (ja) 2018-07-11
CA3183040A1 (en) 2014-10-09
TWI631121B (zh) 2018-08-01
BR112015021540A2 (pt) 2017-07-18
BR122021025053B1 (pt) 2022-09-06
HRP20181273T1 (hr) 2018-11-16
CN111960944A (zh) 2020-11-20
MX365343B (es) 2019-05-30
LT2970263T (lt) 2018-08-27
AU2018203977A1 (en) 2018-06-21
DK2970263T3 (en) 2018-08-13
EP3293185A1 (en) 2018-03-14
EP4019491A1 (en) 2022-06-29
CA2903797A1 (en) 2014-10-09
CN105164128B (zh) 2017-12-12
MX2015012000A (es) 2015-12-01
MX381065B (es) 2025-03-12
IL240779A0 (en) 2015-10-29
PL2970263T3 (pl) 2018-10-31
SG11201507360XA (en) 2015-10-29
RU2015143637A (ru) 2017-04-19
UA118667C2 (uk) 2019-02-25
CL2015002548A1 (es) 2016-03-18
RS57569B1 (sr) 2018-10-31
CY1120576T1 (el) 2019-07-10
UY39848A (es) 2022-09-30
AU2014248742B2 (en) 2018-04-05
CR20150495A (es) 2015-12-03
KR20150128994A (ko) 2015-11-18
JP2016514137A (ja) 2016-05-19
PH12015501960A1 (en) 2016-01-11
CN105164128A (zh) 2015-12-16
CA2903797C (en) 2022-06-21
SG10201701680YA (en) 2017-04-27
KR102230339B1 (ko) 2021-03-23
NZ711315A (en) 2020-10-30
EP3954687A1 (en) 2022-02-16
BR112015021540B1 (pt) 2022-04-19
MY192466A (en) 2022-08-22
CA3090936C (en) 2023-02-07
JP6578037B2 (ja) 2019-09-18
ES2683378T3 (es) 2018-09-26
BR122021025062B1 (pt) 2022-04-19
CN107721851A (zh) 2018-02-23
PH12018501094A1 (en) 2019-11-25
AU2014248742A1 (en) 2015-09-10
AU2018203977B2 (en) 2019-07-11
UY39847A (es) 2022-09-30
SI2970263T1 (sl) 2018-09-28
EP2970263B1 (en) 2018-05-09
HK1216644A1 (en) 2016-11-25
PE20191685A1 (es) 2019-11-19
TW201825491A (zh) 2018-07-16
UY35394A (es) 2014-09-30
RU2660424C2 (ru) 2018-07-06
HK1251231A1 (en) 2019-01-25
TWI735759B (zh) 2021-08-11
IL257109B (en) 2019-01-31
EP3569588A1 (en) 2019-11-20
PT2970263T (pt) 2018-10-03
TW201522334A (zh) 2015-06-16
CA3090936A1 (en) 2014-10-09
CN107721851B (zh) 2021-06-25
PH12015501960B1 (en) 2016-01-11
EP2970263A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
PE20151809A1 (es) Procesos para la preparacion de un agente inductor de la apoptosis
DOP2017000149A (es) Compuestos de triazolopirimidina y usos de los mismos
CU24605B1 (es) Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2
HRP20181679T1 (hr) Amidni spojevi za liječenje hiv
AR098912A1 (es) Inhibidores de syk
AR095265A1 (es) Procesos para la preparación de un agente inductor de la apoptosis
CR20200276A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamientos de la hepatitis b (divisional exp. 2015-0059)
CU20180144A7 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CO7061081A2 (es) Derivados macrocíclicos para el tratamiento de enfermedades
CR20140231A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
MX2020007023A (es) Analogos detiadiazol y metodos para el tratamiento de afecciones relacionadas con la deficiencia del gen de supervivencia de las neuronas motoras (smn).
UY35683A (es) Polimorfo de inhibidores de tirosina quinasa de bazo (syk)
EA201690020A1 (ru) Применение производных пиразолопиридина для лечения рака мочевого пузыря
HUE045892T2 (hu) Eljárás tisztított vizes hidrogénperoxid-oldat elõállítására
UY35333A (es) Compuestos de azabencimidazol
CY1123842T1 (el) Ετεροαρυλικες ενωσεις για τη θεραπευτικη αντιμετωπιση οφθαλμικων νοσων
FR3014105B1 (fr) Procede de fabrication du 1-chloro-2,2-difluoroethane
CU24499B1 (es) Proceso para preparar ésteres de ácido láctico y ácido 2-hidroxi-3-butenoico a partir de azúcares
CR20150245A (es) Proceso novedoso para la elaboración de compuestos para uso en el tratamiento de cáncer
HUE053751T2 (hu) Eljárás iopamidol elõállítására
EA201690696A1 (ru) Способ получения адамантанамидов
MX386134B (es) Proceso para la preparación de 5-fluoro-1h-pirazoles.
HRP20181799T1 (hr) Optimizirana farmaceutska formula, namijenjena liječenju upalnih promjena jednjaka
FR3009555B1 (fr) Procede de preparation de peroxydes organiques
CO7141402A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles